Application of tRF-Tyr-GTA-006 in the preparation of products for predicting lymph node metastasis of lung adenocarcinoma

By discovering tRF-Tyr-GTA-006 as a marker in lung adenocarcinoma, plasma detection is used to achieve accurate prediction of lymph node metastasis in lung adenocarcinoma, solving the problems of low prediction accuracy and insufficient non-invasiveness in the prior art. A radiation-free, minimally invasive diagnostic method is used to improve the sensitivity and specificity of the diagnosis.

CN117987551BActive Publication Date: 2024-11-19CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410114828.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-26
Publication Date
2024-11-19
Estimated Expiration
2044-01-26

AI Technical Summary

Technical Problem

The prior art has low accuracy in predicting lymph node metastasis of lung adenocarcinoma, relies on subjective physician experience and radiation examinations, and lack of non-invasive and reliable biomarkers, resulting in difficulty in selecting treatment options and physical trauma.

Method used

Research has found that tRF-Tyr-GTA-006 is highly expressed in lung adenocarcinoma patients. As a marker of lymph node metastasis in lung adenocarcinoma, a biomarker-based prediction method is provided through the detection of tRF-Tyr-GTA-006 in plasma. , combined with detection preparations and detection kits, the accurate prediction of lymph node metastasis of lung adenocarcinoma is achieved.

Benefits of technology

Through the detection of tRF-Tyr-GTA-006 in plasma, the diagnostic sensitivity and specificity of lymph node metastasis of lung adenocarcinoma is significantly improved, providing a radiation-free and minimally invasive diagnostic method to help clinicians quickly and accurately grasp the patient's condition and Develop personalized treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117987551B_ABST
    Figure CN117987551B_ABST
Patent Text Reader

Abstract

The present invention discloses the application of tRF-Tyr-GTA-006 in the preparation of a product for predicting lymph node metastasis of lung adenocarcinoma. The present invention's research shows that tRF-Tyr-GTA-006 is highly expressed in lung adenocarcinoma tissues and plasma samples with lymph node metastasis. Compared with other cancers with lymph node metastasis, benign lung tumors, squamous cell lung carcinoma, and lung adenocarcinoma without lymph node metastasis, tRF-Tyr-GTA-006 is expressed in the plasma of lung adenocarcinoma patients with lymph node metastasis with certain specificity. Therefore, it can be used as a marker for predicting whether lymph nodes in lung adenocarcinoma are metastatic, and tRF-Tyr-GTA-006 in plasma can relatively accurately predict lymph node metastasis of lung adenocarcinoma. The application of the biomarker to predict the lymph node metastasis status of lung adenocarcinoma provides support for clinicians to quickly and accurately grasp the patient's condition and promptly adopt more personalized prevention and treatment plans.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of lung adenocarcinoma diagnosis, and in particular, to the application of tRF-Tyr-GTA-006 in the preparation of a product for predicting lung adenocarcinoma lymph node metastasis. Background Art

[0002] Lung cancer is one of the cancers with the highest morbidity and mortality rates worldwide. Although the emergence of comprehensive treatment options such as surgery combined with targeted therapy and immunotherapy has improved the clinical efficacy of lung cancer in recent years, its survival rate still needs to be improved.

[0003] Lung cancer lymph node metastasis is one of the main reasons for poor prognosis in lung cancer patients. Studies have shown that for patients with advanced lung cancer without distant metastasis but with lymph node metastasis limited to the thoracic cavity, if the potential lymph node metastasis can be identified before surgery, it can not only avoid excessive surgical treatment for advanced patients, but also guide patients in the middle stage to receive neoadjuvant therapy and improve patient prognosis. Therefore, accurate preoperative judgment of whether lung cancer patients have lymph node metastasis has a great impact on the choice of lung cancer treatment options.

[0004] However, the current preoperative prediction of lung cancer lymph node metastasis status mainly relies on doctors' experience based on CT images. This method is subjective, time-consuming and has a low accuracy rate (the average accuracy rate is about 0.7). 18 F-FDG PET / CT is also limited in its role in evaluating the status of mediastinal lymph node metastasis in lung adenocarcinoma with a diameter of <15 mm. At the same time, CT and PET / CT also have radiation side effects. Mediastinoscopy or endobronchial ultrasound lymph node biopsy, which is radiation-free and can accurately determine the status of lymph node metastasis, is an invasive operation that causes great trauma to the body and can cause a variety of complications after surgery. These examination methods have high requirements on the level of hospital equipment and doctors, and are difficult to promote in a homogeneous manner. Therefore, it is very important to discover and identify biological targets for lymph node metastasis in lung adenocarcinoma.

[0005] Recently, tsRNA (tRNA-derived small RNAs) derived from tRNA has attracted attention. tsRNA is formed by cleavage of precursor tRNA or mature tRNA, and is divided into two categories according to the cleavage position and length, namely tiRNAs (tRNA halves) and tRFs (tRNA-derived fragments). tRFs are formed by cleavage of specific RNA cleavage enzymes in the cytoplasm, and have the characteristics of high conservation and high stability, and are expected to be used as new tumor markers. In addition, abnormal expression of tRFs is related to cancer metastasis, drug resistance, etc.

[0006] The clinical application value of tRFs has been explored in a variety of cancers. CN116377045A discloses an application method for the diagnosis and treatment of hepatocellular carcinoma using tRF-3Thr-CGT. In vivo and in vitro studies have shown that the tRF significantly promotes the invasion and metastasis of hepatocellular carcinoma, and can become a new diagnostic biomarker and therapeutic target for hepatocellular carcinoma. CN113151260A discloses tRF022252 and its application for inhibiting tumor metastasis, and clarifies that tRF022252 derived from arginine-encoding tRNA has a significant effect of inhibiting tumor metastasis, and can reverse the promotion of tumor metastasis by the hypoxic tumor microenvironment, and has no toxic side effects, which lays the foundation for the development and utilization of anti-tumor drugs in the later stage and has great guiding significance. CN110373471A discloses a plasma exosome tRFs marker tRF-Ser-AGA-018 and its application in the diagnosis of breast cancer, which can greatly improve the sensitivity and specificity of disease diagnosis and help the diagnosis of breast cancer. CN108588230A invention discloses a marker for breast cancer diagnosis and a screening method thereof, and obtains a tiRNA marker 5′-tiRNA for breast cancer diagnosis by screening tissue specimens of breast cancer patients. Val . It is a tiRNA that is lowly expressed in breast cancer and is closely related to the proliferation and metastasis of breast cancer. It has potential value in early diagnosis and prognosis. At present, tRFs-related research in the field of lung adenocarcinoma has just started, and there are no clinically accurate tRF-related research or patents that can be used to predict lung adenocarcinoma lymph node metastasis. Exploring new tumor markers that can be used to predict lung adenocarcinoma lymph node metastasis from the perspective of tRFs will help provide new means for clinical diagnosis and treatment. Summary of the invention

[0007] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and to provide the use of tRF-Tyr-GTA-006 as a marker for predicting lymph node metastasis of lung adenocarcinoma in the preparation of a product for predicting lymph node metastasis of lung adenocarcinoma.

[0008] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0009] The present invention found that compared with the tumor tissue and plasma samples of lung adenocarcinoma patients (25 cases), lung squamous cell carcinoma (13 cases), benign lung tumors (7 cases) and lung squamous cell carcinoma (20 cases) with lymph node metastasis, the tRF-Tyr-GTA-006 was highly expressed in the tissue and plasma samples of lung adenocarcinoma (21 cases) with lymph node metastasis. Therefore, tRF-Tyr-GTA-006 can be used as a marker for whether the lymph nodes in lung adenocarcinoma are metastatic. At the same time, the present invention found that the expression of tRF-Tyr-GTA-006 in tumor tissue and plasma samples of lung adenocarcinoma (25 cases of lymph node-negative lung adenocarcinoma and 21 cases of lymph node-positive lung adenocarcinoma) was positively correlated, and in the preoperative and postoperative plasma samples of lung adenocarcinoma patients (21 cases) with lymph node metastasis, tRF-Tyr-GTA-006 was significantly reduced in the postoperative plasma samples. Furthermore, compared with the plasma of patients with gastric cancer (17 cases), breast cancer (13 cases), and colon cancer (15 cases) with lymph node metastasis, the tRF-Tyr-GTA-006 was highly expressed in the plasma of patients with lung adenocarcinoma (21 cases) with lymph node metastasis, indicating that tRF-Tyr-GTA-006 has a certain specificity in patients with lung adenocarcinoma. Through ROC curve analysis, plasma tRF-Tyr-GTA-006 can relatively accurately predict the lymph node metastasis of lung adenocarcinoma and can be used as a marker for predicting lymph node metastasis of lung adenocarcinoma.

[0010] Tumor-derived tRFs in plasma are a new type of biomarker that is stable, minimally invasive, and can be monitored in real time. It can greatly improve the sensitivity and specificity of disease diagnosis. The successful development of the plasma biomarker tRF-Tyr-GTA-006 helps predict the lymph node metastasis status of lung adenocarcinoma, and provides support for clinicians to quickly and accurately understand the patient's condition and adopt more personalized prevention and treatment plans in a timely manner.

[0011] Therefore, the present invention provides the use of tRF-Tyr-GTA-006 as a marker for predicting lymph node metastasis of lung adenocarcinoma in preparing a product for predicting lymph node metastasis of lung adenocarcinoma. The nucleotide sequence of the tRF-Tyr-GTA-006 is shown in SEQ ID No. 1: TCCGGCTCGGAGGACCA.

[0012] The present invention also provides the use of a preparation for detecting the expression level of tRF-Tyr-GTA-006 in preparing a product for predicting lymph node metastasis of lung adenocarcinoma.

[0013] Furthermore, the preparation contains primers for detecting tRF-Tyr-GTA-006.

[0014] Preferably, the primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is shown as SEQ ID No.2, and the nucleotide sequence of the downstream primer is shown as SEQ ID No.3.

[0015] Furthermore, the product is a kit.

[0016] The present invention provides a detection kit for predicting lymph node metastasis of lung adenocarcinoma, which contains a preparation for detecting the expression of the above-mentioned biomarker tRF-Tyr-GTA-006.

[0017] Furthermore, the preparation contains amplification primers for detecting tRF-Tyr-GTA-006.

[0018] Furthermore, the amplification primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is shown in SEQ ID No.2, and the nucleotide sequence of the downstream primer is shown in SEQ ID No.3.

[0019] Furthermore, the detection kit also contains internal reference primers, and the sequences of the internal reference primers are shown in SEQ ID No.4 and SEQ ID No.5.

[0020] Furthermore, the detection sample of the detection kit is a lung adenocarcinoma tumor tissue sample or a plasma sample.

[0021] Preferably, the test sample of the detection kit is a plasma sample.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention provides the use of tRF-Tyr-GTA-006 as a marker for predicting lymph node metastasis of lung adenocarcinoma in the preparation of a product for predicting lymph node metastasis of lung adenocarcinoma. The present invention studies show that tRF-Tyr-GTA-006 is highly expressed in lung adenocarcinoma tissues and plasma samples with lymph node metastasis. Compared with patients with gastric cancer, breast cancer, and colon cancer with lymph node metastasis, the expression of tRF-Tyr-GTA-006 in the plasma of lung adenocarcinoma patients has certain specificity. Therefore, the tRF-Tyr-GTA-006 can be used as a marker for predicting whether lymph nodes in lung adenocarcinoma are metastatic, and plasma tRF-Tyr-GTA-006 can relatively accurately predict lymph node metastasis of lung adenocarcinoma. The AUC value of tRF-Tyr-GTA-006 is 0.88, which has good specificity and sensitivity. The biomarkers are used to predict the lymph node metastasis status of lung adenocarcinoma, providing support for clinicians to quickly and accurately understand the patient's condition and adopt more personalized prevention and treatment plans in a timely manner. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1Figure 2 is the expression of tRF-Tyr-GTA-006 in tumor tissues and plasma of patients with lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tumors; A is the correlation analysis of tRF-Tyr-GTA-006 expression in plasma of patients with lung adenocarcinoma without lymph node metastasis (LN-negative AD), patients with lung adenocarcinoma with lymph node metastasis (LN-positive AD), patients with lung squamous cell carcinoma (LN-negative SCC), patients with benign lung tumors (benign tumor), and patients with lung squamous cell carcinoma with lymph node metastasis (LN-positive SCC); B is the correlation analysis of tRF-Tyr-GTA-006 expression in plasma of patients with lung adenocarcinoma without lymph node metastasis (LN-negative AD), patients with lung adenocarcinoma with lymph node metastasis (LN-positive AD), patients with lung squamous cell carcinoma (LN-negative SCC), patients with benign lung tumors (benign tumor), and patients with lung squamous cell carcinoma with lymph node metastasis (LN-positive SCC). Expression correlation analysis in tumor tissues of SCC.

[0025] Figure 2 is the expression correlation of tRF-Tyr-GTA-006 in lung adenocarcinoma tissue and plasma samples; wherein A is the expression correlation analysis of tRF-Tyr-GTA-006 in lung adenocarcinoma tissue and plasma samples, and B is the expression correlation of tRF-Tyr-GTA-006 in preoperative and postoperative plasma samples of lung adenocarcinoma patients with lymph node metastasis.

[0026] Figure 3 It is the expression of tRF-Tyr-GTA-006 in the plasma of patients with lung adenocarcinoma (AD), gastric cancer (gastricadenocarcinoma), breast cancer (breast cancer), and colon cancer (colon cancer) with lymph node metastasis; wherein A is the result of real-time quantitative PCR analysis, and B is the result of ROC curve analysis. DETAILED DESCRIPTION

[0027] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0028] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0029] Example 1 Expression of tRF-Tyr-GTA-006 in tumor tissues and plasma of patients with lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tumors

[0030] The present invention first studies the expression of tRF-Tyr-GTA-006 (sequence as shown in SEQ ID No. 1) in tumor tissue and plasma of patients with lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tumors. The specific research samples are tumor tissue and plasma samples of patients with lung adenocarcinoma without lymph node metastasis (25 cases), patients with lung adenocarcinoma with lymph node metastasis (21 cases), patients with lung squamous cell carcinoma (13 cases), patients with benign lung tumors (7 cases), and patients with lung squamous cell carcinoma with lymph node metastasis (20 cases).

[0031] The specific experimental steps are as follows:

[0032] 1. Plasma separation of peripheral blood: peripheral blood was collected from patients 1 day before and 3 days after surgery, centrifuged at 1900rpm for 10 minutes, and then the light yellow supernatant was carefully aspirated. About 2mL of plasma can be collected from 6mL of peripheral blood. Centrifuged at 16000rpm for 10 minutes at 4°C, and then the plasma was dispensed into 2mL nucleic acid-free EP tubes and stored in liquid nitrogen until use;

[0033] 2. Freezing and keeping the cancer tissue samples of the cancer patients from which the corresponding blood samples were collected in liquid nitrogen;

[0034] 3. Total RNA from tumor tissue and plasma was extracted using Trizol reagent (Takara, Japan). 1 mL of Trizol reagent was added to the sample, and the mixture was centrifuged at 12000 rpm and 4°C for 5 min. The supernatant was taken and 200 μL of chloroform was added. After vigorous shaking, the mixture was allowed to stand for 15 min to allow for natural phase separation. The mixture was centrifuged at 12000 rpm and 4°C for 15 min. The colorless aqueous phase was carefully aspirated into a new 1.5 mL centrifuge tube, and an equal volume of isopropanol was added. The mixture was fully mixed and allowed to stand for 10 min. The mixture was placed at -20°C for 1 h, and centrifuged at 12000 rpm and 4°C for 10 min. The supernatant was discarded, and 1 mL of 75% ethanol was added to wash the RNA precipitate. The mixture was centrifuged at 8000 rpm and 4°C for 5 min, and the ethanol was discarded. The mixture was dried at room temperature for 5 min to 10 min to evaporate the residual ethanol. 50 μL of RNase-free water was added to dissolve the mixture, and the integrity of the total RNA was detected by 1% agarose gel electrophoresis. At the same time, an appropriate amount of total RNA was taken to determine its OD260, OD280, and concentration. The RNA solution was aliquoted and stored at -80°C for later use. The RNA was analyzed by Nano Drop ND-1000 (Nano Drop Technologies, Wilmington, DE, USA) to determine the purity and concentration of total RNA samples;

[0035] 4. Perform 3'-terminal deacylation, remove 3'-cP and 5'-P tailing and demethylation pretreatment on RNA to remove modifications that interfere with cDNA construction;

[0036] 5. tRFs were reverse transcribed using the miRNA 1st Strand cDNA Synthesis Kit (Accurate) with a reaction volume of 10 μL and diluted to 100 μL. cDNA was amplified using SYBR Green Pro Taq HS Premix (Accurate) and the Light Cycler 480 detection system (Roche Diagnostics, Basel, Switzerland) for qRT-PCR. U6 was used as the internal reference for tRF. 2 -ΔΔCt The expression of relevant tRF was detected by the method, and each sample was tested three times. The sequence information of all primers is shown in Table 1 below:

[0037] Table 1

[0038]

[0039]

[0040] Through the above experimental steps, the samples were subjected to real-time quantitative PCR analysis of tRF-Tyr-GTA-006. Figure 1 A and Figure 1 B It can be seen that tRF-Tyr-GTA-006 is significantly highly expressed in tumor tissues and plasma of lung adenocarcinoma with lymph node metastasis, and can be used as a marker for lymph node metastasis in lung adenocarcinoma.

[0041] Example 2 Correlation of tRF-Tyr-GTA-006 expression in lung adenocarcinoma tissue and plasma samples

[0042] Referring to the experimental steps described in Example 1, real-time quantitative PCR analysis of tRF-Tyr-GTA-006 was performed on lung adenocarcinoma tissue and plasma samples, and the lung adenocarcinoma tissue and plasma samples were specifically tumor tissue and plasma samples of patients with lymph node-negative lung adenocarcinoma (25 cases) and lymph node-positive lung adenocarcinoma (21 cases). According to the analysis results, Figure 2 A shows that the expression of tRF-Tyr-GTA-006 in lung adenocarcinoma tumor tissue and plasma is positively correlated, indicating that there is a certain correlation between the expression of tRF-Tyr-GTA-006 in plasma and the expression in lung adenocarcinoma tissue.

[0043] Example 3 Correlation of tRF-Tyr-GTA-006 expression in plasma samples before and after lung adenocarcinoma surgery

[0044] Referring to the experimental steps described in Example 1, in the population of lung adenocarcinoma with lymph node metastasis (21 cases), the plasma samples of the same patient before and after lung adenocarcinoma surgery were analyzed by real-time quantitative PCR for tRF-Tyr-GTA-006. Figure 2 B shows that the expression of tRF-Tyr-GTA-006 in the plasma after surgery of lung adenocarcinoma with lymph node metastasis is significantly lower than that in the plasma before surgery, indicating that the expression change of tRF-Tyr-GTA-006 in plasma is partly derived from the release of the tumor.

[0045] Example 4 Expression of tRF-Tyr-GTA-006 in the plasma of patients with lung adenocarcinoma, gastric cancer, breast cancer, and colon cancer with lymph node metastasis

[0046] Referring to the experimental steps described in Example 1, plasma samples from patients with lung adenocarcinoma with lymph node metastasis (21 cases) and patients with gastric cancer (17 cases), breast cancer (13 cases), and colon cancer (15 cases) with lymph node metastasis were subjected to real-time quantitative PCR analysis of tRF-Tyr-GTA-006. Figure 3 As shown in A, tRF-Tyr-GTA-006 is significantly highly expressed in the plasma of patients with lung adenocarcinoma with lymph node metastasis, and there is no significant difference in expression in other cancers with lymph node metastasis, indicating that tRF-Tyr-GTA-006 has a certain specificity in patients with lung adenocarcinoma with lymph node metastasis. Figure 3 As can be seen from B, the AUC value of tRF-Tyr-GTA-006 is 0.88, indicating that plasma tRF-Tyr-GTA-006 has good specificity and sensitivity when predicting lymph node metastasis of lung adenocarcinoma.

[0047] The above technical solution is only one embodiment of the present invention. For those skilled in the art, it is easy to make various types of improvements or deformations based on the application methods and principles disclosed in the present invention, and it is not limited to the method described in the above specific embodiments of the present invention. Therefore, the above described method is only preferred and has no restrictive significance. As long as tRF-Tyr-GTA-006 is used to predict whether there is lymph node metastasis in lung adenocarcinoma, it falls within the scope of protection of this patent.

Claims

1. Use of primers for detecting the expression level of tRF-Tyr-GTA-006 in the preparation of a product for predicting lymph node metastasis of lung adenocarcinoma, characterized in that: The nucleotide sequence of the tRF-Tyr-GTA-006 is shown in SEQ ID No.

1.

2. The application according to claim 1, characterized in that: The primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is shown as SEQ ID No.2, and the nucleotide sequence of the downstream primer is shown as SEQ ID No.3.

Citation Information

Cited By

  • Application of biomarker in tumor lymph node metastasis risk diagnosis and treatment

    CN120948794A